Damora Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Shows the company protects its leaders legally, which is standard governance practice for all public companies.
Company moved its legal home country, which can affect taxes and rules but doesn't change day-to-day business.
Shareholders voted on who leads the company and who checks its finances, key decisions for company oversight.
Companies report quarterly to show investors how much money they made and spent each three months.
Leadership change in finance role means a new person now controls the company's money and accounting.
When a company fires its accountant, investors want to know why to ensure nothing is hidden.
New CEO from Arcus Biosciences sets strategy and direction for the entire company's future.
Stocky reads Damora Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Damora Therapeutics, Inc.'s most recent tracked filing was a 8-K on 20 Jul 2026: Updated director and officer indemnification agreements effective July 16.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.